About FibroGen
FibroGen is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutics to treat serious unmet medical needs. The company specializes in fibrosis, anemia, and oncology, with a particular focus on hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) pathways. FibroGen went public in 2013 and has developed several drug candidates including roxadustat for anemia and pamrevlumab for fibrotic diseases. The company has partnerships with major pharmaceutical companies and has advanced multiple compounds through clinical trials.
Investors & Backers
FibroGen has received investment from 1 venture capital firm.
Full portfolios: Versant Ventures portfolio
Frequently Asked Questions
What does FibroGen do?
Biopharmaceutical company focused on developing therapies for fibrotic diseases, anemia, and cancer through innovative drug discovery.
Who invested in FibroGen?
FibroGen has received investment from Versant Ventures. These venture capital firms and investors provide both capital and strategic support.
When was FibroGen founded?
FibroGen was founded in 1993 and is headquartered in San Francisco, CA.
What sector is FibroGen in?
FibroGen operates in the Biotech sector. Biopharmaceutical company focused on developing therapies for fibrotic diseases, anemia, and cancer through innovative drug discovery.
The operating system for private capital.
Archstone runs the back office for venture, PE, real estate, and credit funds — LP reporting, capital calls, portfolio tracking, and fund accounting, in one platform. Now in alpha.
Company Details
- Sector
- Biotech
- Headquarters
- San Francisco, CA
- Founded
- 1993
- Status
- Active
- Last Funding Stage
- IPO
